RxDoctor Payments Data

James Demarco, MD

Nephrology · Weston, WVNPI 1619946936

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.8% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Akebia Therapeutics Inc at 40.4% of the total.

$2,037in general payments, 2019–2025

Across 72 payments — averaging $28.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Akebia Therapeutics Inc$824
  • Amgen$228
  • AstraZeneca$148
  • Ardelyx, Inc.$127
  • GSK$126
  • Nxstage Medical, Inc.$119
  • plus $466 from 6 others

What the payments were for

  • Food & beverage$2,01399%
  • Education$251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,037 in reported general payments places this provider in the 65th percentile of 55 nephrology providers in West Virginia.

See all nephrology providers in West Virginia

Medicare billing

Part B allowed, 2024
$143,201
Medicare patients
245
Services billed
1,556

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AuryxiaFerric Citrate52$58,848
RenvelaSevelamer Carbonate14$17,909
Sevelamer Carbonate127$17,505
VeltassaPatiromer Calcium Sorbitex19$15,907
LokelmaSodium Zirconium Cyclosilicate16$11,993
Calcium Acetate33$3,614
Gentamicin Sulfate46$585
Pantoprazole Sodium23$418
Promethazine Hcl22$372
Paricalcitol12$342
Midodrine Hcl19$328
Labetalol Hcl11$302
Zolpidem Tartrate22$237
Gabapentin21$227
Carvedilol19$203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Akebia Therapeutics IncAuryxia$824$58,84852 claims
AstraZenecaLokelma$148$11,99316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 55 nephrology providers in West Virginia.

Other nephrology in Weston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →